Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia
NCT03686345 · Niguarda Hospital · PHASE2 · terminated · last registry update 2025-02-25 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “didn't reach the primary endpoint” | Open Targets' class: negative | Registry record, Niguarda Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FLT3 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-23Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Gilteritinib + Venetoclax (NCT07425808)
- 2026-02-12Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Gilteritinib + Azacitidine + Venetoclax + Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib (NCT07407140)
- 2026-01-05Results posted on the registry: Astellas Pharma Global Development, Inc., gilteritinib + fludarabine (NCT04240002)
- 2026-01-05Also stopped (terminated): Astellas Pharma Global Development, Inc., gilteritinib + fludarabine (NCT04240002)
- 2025-12-04Phase 3 first posted: Nanfang Hospital, Southern Medical University, Sorafenib (SORA) + Venetoclax (VEN) (NCT07264010)
- 2025-11-05Results posted on the registry: University of Nebraska, Cytarabine + Decitabine (NCT03226418)
- 2025-09-12Results posted on the registry: Astellas Pharma Global Development, Inc., gilteritinib + azacitidine (NCT02752035)
- 2025-05-15Phase 3 first posted: Ruijin Hospital, Decitabine + Sorafenib (BAY-43-9006)，giritinib (NCT06972641)
- 2025-03-07Also stopped (terminated): Aptose Biosciences Inc., CG-806 (NCT04477291)
- 2025-02-28Results posted on the registry: PrECOG, LLC., Gilteritinib + Midostaurin (NCT03836209)
- 2025-02-11Results posted on the registry: Novartis Pharmaceuticals, Midostaurin + Placebo (NCT03280030)
- 2025-01-14Results posted on the registry: Astellas Pharma Inc, Gilteritinib + Cytarabine (NCT03182244)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-10-16Results posted on the registry: Astellas Pharma Inc, Gilteritinib + Idarubicin (NCT02310321)
- 2024-10-01Also stopped (withdrawn): Guenther Koehne, CPX-351 + Midostaurin (NCT04982354)
- 2024-09-19Results posted on the registry: Astellas Pharma Global Development, Inc., gilteritinib + Placebo (NCT02997202)
- 2024-09-19Results posted on the registry: M.D. Anderson Cancer Center, Quizartinib + Venetoclax (NCT03735875)
- 2024-09-19Also stopped (terminated): M.D. Anderson Cancer Center, Quizartinib + Venetoclax (NCT03735875)
- 2024-08-07Results posted on the registry: Kronos Bio, Lanraplenib + Gilteritinib (NCT05028751)
- 2024-08-07Also stopped (terminated): Kronos Bio, Lanraplenib + Gilteritinib (NCT05028751)
- 2024-07-23Results posted on the registry: National Cancer Institute (NCI), Azacitidine + Cytarabine (NCT03092674)
- 2024-02-29Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against FLT3 (NCT06285136)
- 2024-02-28Results posted on the registry: M.D. Anderson Cancer Center, Azacitidine + Cytarabine (NCT01892371)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision